{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:15Z","timestamp":1791919455014,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13058-017-0807-8","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:53:56Z","timestamp":1486688036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2\u2212 breast cancer that had progressed during or after prior endocrine therapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Antonino","family":"Musolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Denduluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bonnefoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Deudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"issue":"2","key":"807_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"807_CR2","volume-title":"Global cancer facts & figures","author":"American Cancer Society","year":"2015","unstructured":"American Cancer Society. Global cancer facts & figures. 3rd ed. Atlanta: American Cancer Society; 2015.","edition":"3"},{"issue":"5","key":"807_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/bcr452","volume":"4","author":"E Anderson","year":"2002","unstructured":"Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002;4(5):197\u2013201.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"807_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","volume":"123","author":"M Nadji","year":"2005","unstructured":"Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21\u20137.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"807_CR5","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.","journal-title":"J Natl Cancer Inst"},{"key":"807_CR6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s40064-015-1538-x","volume":"4","author":"TL Schwartz","year":"2015","unstructured":"Schwartz TL, Veerapong J, Hinyard L. Her2 positivity and race predict higher mastectomy rates: a SEER database analysis. Springerplus. 2015;4:715.","journal-title":"Springerplus"},{"key":"807_CR7","doi-asserted-by":"publisher","unstructured":"Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, et al. HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable. Eur J Cancer Care (Engl). doi: 10.1111\/ecc.12404 .","DOI":"10.1111\/ecc.12404"},{"issue":"10","key":"807_CR8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","volume":"25","author":"F Cardoso","year":"2014","unstructured":"Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Ann Oncol. 2014;25(10):1871\u201388.","journal-title":"Ann Oncol"},{"key":"807_CR9","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. Version 2. Fort Washington, PA: NCCN; 2016."},{"issue":"7","key":"807_CR10","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","volume":"16","author":"SR Johnston","year":"2010","unstructured":"Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16(7):1979\u201387.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"807_CR11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","volume":"21","author":"F Cardoso","year":"2012","unstructured":"Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International Consensus Guidelines for Advanced Breast Cancer (ABC 1). Breast. 2012;21(3):242\u201352.","journal-title":"Breast"},{"issue":"1","key":"807_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-012-0277-1","volume":"15","author":"M Gnant","year":"2013","unstructured":"Gnant M. The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. Curr Oncol Rep. 2013;15(1):14\u201323.","journal-title":"Curr Oncol Rep"},{"key":"807_CR13","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.14694\/EDBK_159198","volume":"35","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Vidula N, Ma C. Improving response to hormone therapy in breast cancer: new targets, new therapeutic options. Am Soc Clin Oncol Educ Book. 2016;35:e40\u201354.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"807_CR14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"807_CR15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris 3rd HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870\u201384.","journal-title":"Adv Ther"},{"issue":"1","key":"807_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"3","key":"807_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"7","key":"807_CR18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/14728222.2011.566217","volume":"15","author":"C Heinzle","year":"2011","unstructured":"Heinzle C, Sutterluty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets. 2011;15(7):829\u201346.","journal-title":"Expert Opin Ther Targets"},{"issue":"7148","key":"807_CR19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","volume":"447","author":"DF Easton","year":"2007","unstructured":"Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087\u201393.","journal-title":"Nature"},{"issue":"2","key":"807_CR20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-015-3672-0","volume":"155","author":"EA Ruiz-Narvaez","year":"2016","unstructured":"Ruiz-Narvaez EA, Haddad SA, Lunetta KL, Yao S, Bensen JT, Sucheston-Campbell LE, et al. Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER Consortium. Breast Cancer Res Treat. 2016;155(2):355\u201363.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"807_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-015-3301-y","volume":"150","author":"F Andr\u00e9","year":"2015","unstructured":"Andr\u00e9 F, Cortes J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat. 2015;150(1):1\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"807_CR22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ijc.2910540305","volume":"54","author":"S Jaakkola","year":"1993","unstructured":"Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrh\u00f6nen S, et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer. 1993;54(3):378\u201382.","journal-title":"Int J Cancer"},{"issue":"3","key":"807_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910590314","volume":"59","author":"J Jacquemier","year":"1994","unstructured":"Jacquemier J, Adelaide J, Parc P, Penault-Llorca F, Planche J, DeLapeyriere O, et al. Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer. 1994;59(3):373\u20138.","journal-title":"Int J Cancer"},{"issue":"2","key":"807_CR24","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr1665","volume":"9","author":"S Elbauomy Elsheikh","year":"2007","unstructured":"Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9(2):R23.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"807_CR25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-08-1791","volume":"15","author":"F Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15(2):441\u201351.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"807_CR26","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085\u201394.","journal-title":"Cancer Res"},{"issue":"7418","key":"807_CR27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"14","key":"807_CR28","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/onc.2009.489","volume":"29","author":"N Turner","year":"2010","unstructured":"Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013\u201323.","journal-title":"Oncogene"},{"issue":"4","key":"807_CR29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/cas.12897","volume":"107","author":"M Tomiguchi","year":"2016","unstructured":"Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Fujiwara S, et al. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive\/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Sci. 2016;107(4):491\u20138.","journal-title":"Cancer Sci"},{"issue":"9","key":"807_CR30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ctrv.2014.08.003","volume":"40","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordan J, et al. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. Cancer Treat Rev. 2014;40(9):1048\u201355.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"807_CR31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/jso.22120","volume":"105","author":"S Sun","year":"2012","unstructured":"Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2012;105(8):773\u20139.","journal-title":"J Surg Oncol"},{"issue":"12","key":"807_CR32","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/ijc.26304","volume":"130","author":"DC Tomlinson","year":"2012","unstructured":"Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer. 2012;130(12):2857\u201366.","journal-title":"Int J Cancer"},{"issue":"10","key":"807_CR33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/onc.2009.432","volume":"29","author":"A Roidl","year":"2010","unstructured":"Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ, et al. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene. 2010;29(10):1543\u201352.","journal-title":"Oncogene"},{"issue":"23","key":"807_CR34","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2005.04.8587","volume":"24","author":"C Thussbas","year":"2006","unstructured":"Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006;24(23):3747\u201355.","journal-title":"J Clin Oncol"},{"issue":"1","key":"807_CR35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, et al. A phase Ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2\u2212 metastatic breast cancer. Clin Cancer Res. 2017;23(1):26\u201334.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"807_CR36","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1158\/1078-0432.CCR-05-0358","volume":"11","author":"L Menezes DE de","year":"2005","unstructured":"de Menezes DE L, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res. 2005;11(14):5281\u201391.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"807_CR37","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1158\/0008-5472.CAN-09-4479","volume":"70","author":"JH Dey","year":"2010","unstructured":"Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K\/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010;70(10):4151\u201362.","journal-title":"Cancer Res"},{"issue":"13","key":"807_CR38","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","volume":"19","author":"F Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 F, Bachelot T, Campone M, Dalenc F, Perez-Garcia J, Hurvitz SA, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19(13):3693\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"807_CR39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/bjs.9021","volume":"100","author":"S Kashiwagi","year":"2013","unstructured":"Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Kawajiri H, Ogawa Y, et al. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. Br J Surg. 2013;100(4):490\u20136.","journal-title":"Br J Surg"},{"issue":"7","key":"807_CR40","doi-asserted-by":"crossref","first-page":"e102176","DOI":"10.1371\/journal.pone.0102176","volume":"9","author":"S Jansson","year":"2014","unstructured":"Jansson S, Bendahl PO, Grabau DA, Falck AK, Fern\u00f6 M, Aaltonen K, et al. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFR\u03b1, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS One. 2014;9(7):e102176.","journal-title":"PLoS One"},{"key":"807_CR41","doi-asserted-by":"crossref","unstructured":"Angevin E, Lopez JA, Pande A, Moldovan C, Shi M, Soria JC, et al. TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: a phase I\/II dose finding and biomarker study. J Clin Oncol. 2009;27:(Suppl 15). [abstract 3563].","DOI":"10.1200\/jco.2009.27.15_suppl.3563"},{"issue":"9","key":"807_CR42","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/bjc.2013.594","volume":"109","author":"YK Kang","year":"2013","unstructured":"Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, et al. Phase II study of dovitinib in patients with metastatic and\/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer. 2013;109(9):2309\u201315.","journal-title":"Br J Cancer"},{"issue":"18","key":"807_CR43","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.ejca.2014.10.013","volume":"50","author":"MI Milowsky","year":"2014","unstructured":"Milowsky MI, Dittrich C, Duran I, Jagdev S, Millard FE, Sweeney CJ, et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014;50(18):3145\u201352.","journal-title":"Eur J Cancer"},{"key":"807_CR44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00280-015-2681-3","volume":"75","author":"JR Infante","year":"2015","unstructured":"Infante JR, Ramanathan RK, George D, Tan E, Quinlan M, Liu A, et al. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). Cancer Chemother Pharmacol. 2015;75:729\u201337.","journal-title":"Cancer Chemother Pharmacol"},{"key":"807_CR45","doi-asserted-by":"crossref","unstructured":"Dienstmann R, Andre F, Soria J, Tabernero J, De Braud FGM, Cereda R, et al. Significant antitumor activity of E-3810, a novel FGFR and VEGFR inhibitor, in patients with FGFR1 amplified breast cancer. Ann Oncol. 2012;23:(Suppl 9). [abstract 3190]. \u115f","DOI":"10.1016\/S0923-7534(20)32898-2"},{"key":"807_CR46","doi-asserted-by":"crossref","unstructured":"Dienstmann R, Bahleda R, Adamo B, Rodon J, Varga A, Gazzah A, et al. First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Cancer Res. 2014;74:(Suppl 19). [abstract CT325]. \u115f","DOI":"10.1158\/1538-7445.AM2014-CT325"},{"key":"807_CR47","doi-asserted-by":"crossref","unstructured":"Sequist LV, Cassier P, Varga A, Tabernero J, Schellens JHM, Delord J, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res. 2014;74:(Suppl 19). [abstract CT326].","DOI":"10.1158\/1538-7445.AM2014-CT326"},{"key":"807_CR48","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr3379","volume":"15","author":"A Issa","year":"2013","unstructured":"Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, et al. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res. 2013;15:R8.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"807_CR49","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.2010.31.6877","volume":"29","author":"F Andre","year":"2011","unstructured":"Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol. 2011;29(10):1236\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"807_CR50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.molonc.2014.09.011","volume":"9","author":"DVT Catenacci","year":"2015","unstructured":"Catenacci DVT. Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9(5):967\u201396.","journal-title":"Mol Oncol"},{"issue":"2","key":"807_CR51","first-page":"13","volume":"3","author":"C Tourneau Le","year":"2014","unstructured":"Le Tourneau C, Kamal M, Alt M, Verlingue L, Servois V, Sablin M, et al. The spectrum of clinical trials aiming at personalizing medicine. Chin Clin Oncol. 2014;3(2):13.","journal-title":"Chin Clin Oncol"},{"key":"807_CR52","doi-asserted-by":"crossref","unstructured":"Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, et al. National Cancer Institute\u2019s precision medicine initiates for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014:71\u20136. doi:10.14694\/EdBook_AM.2014.34.71.","DOI":"10.14694\/EdBook_AM.2014.34.71"},{"issue":"2","key":"807_CR53","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.molonc.2012.02.008","volume":"6","author":"M Arnedos","year":"2012","unstructured":"Arnedos M, Andr\u00e9 F, Farace F, Lacroix L, Besse B, Robert C, et al. The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. Mol Oncol. 2012;6(2):204\u201310.","journal-title":"Mol Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-017-0807-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T05:29:37Z","timestamp":1601616577000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-017-0807-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s13058-017-0807-8","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]},"article-number":"18"}}